Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average – Time to Sell?

Compugen Ltd. (NASDAQ:CGEN) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.62 and traded as high as $1.85. Compugen shares last traded at $1.82, with a volume of 204,815 shares.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright started coverage on Compugen in a research note on Wednesday, January 7th. They issued a “buy” rating and a $4.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. Finally, Wall Street Zen raised Compugen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Compugen currently has an average rating of “Hold” and a consensus price target of $4.00.

Compugen Stock Performance

The business has a 50 day moving average price of $1.72 and a 200-day moving average price of $1.62.

Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. Compugen had a negative net margin of 400.10% and a negative return on equity of 53.60%. The business had revenue of $1.89 million for the quarter, compared to the consensus estimate of $1.47 million. On average, research analysts forecast that Compugen Ltd. will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Compugen

A number of institutional investors and hedge funds have recently modified their holdings of CGEN. Two Sigma Investments LP grew its holdings in Compugen by 10.6% during the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 18,929 shares during the period. Franklin Resources Inc. acquired a new stake in shares of Compugen in the second quarter valued at approximately $56,000. Osaic Holdings Inc. boosted its stake in shares of Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 34,045 shares during the period. Raymond James Financial Inc. boosted its stake in shares of Compugen by 51.0% during the 3rd quarter. Raymond James Financial Inc. now owns 101,256 shares of the biotechnology company’s stock worth $149,000 after acquiring an additional 34,215 shares during the period. Finally, R Squared Ltd acquired a new position in shares of Compugen during the 2nd quarter worth approximately $71,000. 12.22% of the stock is owned by institutional investors.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.